Literature DB >> 17895300

Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome.

A W S de Souza1, N P Silva, J F de Carvalho, V D'Almeida, M A E Noguti, E I Sato.   

Abstract

The aim of this study was to evaluate traditional risk factors for coronary artery disease (CAD), homocysteine, anti-oxidized low-density lipoprotein (anti-oxLDL), anti-lipoprotein lipase (anti-LPL) and endothelin-1 (ET-1) in patients with primary anti-phospholipid syndrome (APS), furthermore verify possible association among these variables and arterial thrombosis. Thirty-eight women with primary APS and 30 age-and-sex-matched controls were evaluated. Patients presented higher-LDL and triglycerides levels and lower-HDL levels than controls. Anti-LPL antibodies were not detected in both groups. The mean number of risk factors was higher in patients than in controls (P = 0.030). Anti-oxLDL antibodies, homocysteine and ET-1 mean levels were similar between groups, but abnormal homocysteine levels were found only among primary APS patients (P = 0.031). Hypertension and the presence of at least one risk factor for CAD were more prevalent in patients with arterial involvement than those without. Homocysteine levels and mean number of risk factors for CAD were significantly higher in patients with arterial thrombosis than controls. In a multivariate analysis hypertension was the only independently associated with arterial thrombosis (OR 14.8, 95% CI = 2.1-100.0, P = 0.006). This study showed that in primary APS patients other risk factors besides anti-phospholipid antibodies contribute for the occurrence of arterial events and the most important factor was hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17895300     DOI: 10.1177/0961203307081847

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

1.  Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort.

Authors:  Aleksandra Djokovic; Ljudmila Stojanovich; Natasa Stanisavljevic; Sandra Djokic; Branka Filipovic; Predrag Matic; Milomir Milanovic; Svetlana Apostolovic; Jovica Saponjski
Journal:  Clin Rheumatol       Date:  2022-01-11       Impact factor: 2.980

2.  Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study.

Authors:  Hui Jiang; Chu-Han Wang; Nan Jiang; Jing Li; Chan-Yuan Wu; Qian Wang; Meng-Tao Li; Xin-Ping Tian; Jiu-Liang Zhao; Yan Zhao; Xiao-Feng Zeng
Journal:  Arthritis Res Ther       Date:  2021-05-08       Impact factor: 5.156

Review 3.  Cardiovascular risk factors in the antiphospholipid syndrome.

Authors:  Felipe Freire da Silva; Roger Abramino Levy; Jozélio Freire de Carvalho
Journal:  J Immunol Res       Date:  2014-07-13       Impact factor: 4.818

4.  Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus.

Authors:  Eleana Bolla; Nikolas Tentolouris; Petros P Sfikakis; Maria G Tektonidou
Journal:  Lupus Sci Med       Date:  2021-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.